Chandrasekaran E V, Jain R K, Matta K L
Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York 14263.
J Biol Chem. 1992 Nov 25;267(33):23806-14.
Several N-acetyllactosamine (LacNAc) derivatives were tested as acceptors for alpha 1,3-L-fucosyltransferase present in human ovarian cancer sera and ovarian tumor. The enzyme of the soluble fraction of tumor was purified to apparent homogeneity by chromatography on bovine IgG glycopeptide-Sepharose followed by Sephacryl S-200 (M(r) < 67,000). As compared with 2'-methyl LacNAc, 3'-sulfo LacNAc was about 5-fold more sensitive in measuring alpha 1,3-fucosyltransferase in sera (Km, 3'-sulfo LacNAc, 0.12 mM; 2'-methyl LacNAc, 6.67 mM). When ovarian cancer serum was the enzyme source, either the sulfate group or a sialyl moiety at C-3' of LacNAc enhanced the acceptor ability (341 and 242%, respectively), whereas the sulfate group at C-2' or C-6' reduced the activity (22-36%); sulfate at C-6 or fucose at C-2' increased the activity (172 and 253%). The beta-benzylation of the reducing end, in general, increased the activity 2-3-fold. The enzyme of the soluble fraction of tumor exhibited more activity toward 3'-sulfo LacNAc (447%), 2'-fucosyl-LacNAc (436%), and 6-sulfo LacNAc (272%). Very low activity was observed with 3'-sialyl LacNAc (12.4%), 2'-sulfo LacNAc (33%), and 6'-sulfo LacNAc (5%); Fuc alpha 1,2Gal beta 1,3GlcNAc beta-O-p-nitrophenyl (166%), 2-methyl Gal beta 1,3GlcNAc beta-O-benzyl (204%), and 3-sulfo Gal beta 1,3GlcNAc (415%) also acted as acceptors, indicating the coexistence of alpha 1,3- and alpha 1,4-fucosyltransferase. The tumor particulate enzyme behaved entirely different, exhibiting low activity with 3'-sulfo LacNAc (39%) and 2'-fucosyl-LacNAc (148%); 3'-sialyl, 6'-sulfo, 6-sulfo, or 2'-sulfo LacNAc were 3, 43, 53, and 10% active, respectively. Thus, the ovarian cancer serum alpha 1,3-fucosyltransferase acts equally well on H-type 2,3'-sialyl LacNAc and 3'-sulfo LacNAc, but not on H-type 1. The enzyme of soluble tumor fraction acts on H-type 2,3'-sulfo LacNAc as well as H-type 1 but poorly on 3'-sialyl LacNAc. The tumor particulate enzyme acts on H-type 2 but poorly on 3'-sulfo or 3'-sialyl LacNAc and is inactive with H-type 1. When normal serum was examined with synthetic acceptors, > 80% activity was found as alpha 1,2-fucosyltransferase and the rest as alpha 1,3-fucosyltransferase. A screening of 21 ovarian cancer and 3 normal sera (3'-sulfo LacNAc as acceptor) showed 17-572% increase (average increase, 188%) of alpha 1,3-fucosyltransferase activity in cancer.(ABSTRACT TRUNCATED AT 400 WORDS)
测试了几种N-乙酰乳糖胺(LacNAc)衍生物作为人卵巢癌血清和卵巢肿瘤中存在的α1,3-L-岩藻糖基转移酶的受体。通过在牛IgG糖肽-琼脂糖凝胶上进行色谱分离,然后在Sephacryl S-200(M(r) < 67,000)上进一步分离,将肿瘤可溶性部分的酶纯化至表观均一性。与2'-甲基LacNAc相比,3'-磺基LacNAc在测量血清中的α1,3-岩藻糖基转移酶时敏感性约高5倍(Km,3'-磺基LacNAc为0.12 mM;2'-甲基LacNAc为6.67 mM)。当以卵巢癌血清为酶源时,LacNAc C-3'位的硫酸基团或唾液酸部分增强了受体能力(分别提高341%和242%),而C-2'或C-6'位的硫酸基团降低了活性(降低22 - 36%);C-6位的硫酸基团或C-2'位的岩藻糖增加了活性(分别提高172%和253%)。还原端的β-苄基化通常使活性提高2 - 3倍。肿瘤可溶性部分的酶对3'-磺基LacNAc(447%)、2'-岩藻糖基-LacNAc(436%)和6-磺基LacNAc(272%)表现出更高的活性。观察到3'-唾液酸LacNAc(12.4%)、2'-磺基LacNAc(33%)和6'-磺基LacNAc(5%)活性非常低;Fucα1,2Galβ1,3GlcNAcβ-O-对硝基苯基(166%)、2-甲基Galβ1,3GlcNAcβ-O-苄基(204%)和3-磺基Galβ1,3GlcNAc(415%)也可作为受体,表明α1,3-和α1,4-岩藻糖基转移酶共存。肿瘤颗粒酶的表现完全不同,对3'-磺基LacNAc(39%)和2'-岩藻糖基-LacNAc(代表原文中2'-fucosyl-LacNAc,148%)活性较低;3'-唾液酸、6'-磺基、6-磺基或2'-磺基LacNAc的活性分别为3%、43%、53%和10%。因此,卵巢癌血清α1,3-岩藻糖基转移酶对H-2型、3'-唾液酸LacNAc和3'-磺基LacNAc作用效果相同,但对H-1型不起作用。肿瘤可溶性部分的酶对H-2型、3'-磺基LacNAc以及H-1型都有作用,但对3'-唾液酸LacNAc作用较差。肿瘤颗粒酶对H-2型有作用,但对3'-磺基或3'-唾液酸LacNAc作用较差,对H-1型无活性。当用合成受体检测正常血清时,发现> 80%的活性为α1,2-岩藻糖基转移酶活性,其余为α1,3-岩藻糖基转移酶活性。对21份卵巢癌血清和3份正常血清(以3'-磺基LacNAc为受体)进行筛查显示,癌症中α1,3-岩藻糖基转移酶活性增加了17 - 572%(平均增加188%)。